Angiogenesis and Blood Perfusion Effect of HGF Gene Therapy in PAD Patients

A Double-Blind, Randomized, Placebo-Controlled, Single Center Study to Assess the Angiogenesis and Blood Perfusion Effect of NL003 in Patients With Critical Limb Ischemia by PETCT-RGD and MIBI

The purpose of this study is to evaluate whether PET/CT-RGD or MIBI can be used for the angiogenesis assessment of NL003 in PAD patients.

Study Overview

• Status: Recruiting
• Conditions: Peripheral Artery Disease
• Intervention / Treatment: Drug: NL003; Drug: Placebo

Detailed Description

Hepatocyte growth factor (HGF) gene therapy has been shown to be a potential choice for CLI patients without surgical option. NL003, which is a DNA plasmid that contains novel genomic cDNA hybrid human HGF coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723. Animal studies showed that NL003 inducing angiogenesis in the affected limb and result in an increase in tissue perfusion. Our previous phase II clinical trial has suggested the successful limb-salvaging capacity of NL003 in treatment of patients with CLTI.

In this study we will use 68Ga RGD PET/CT and 99mTc MIBI SPECT imaging methods to evaluate the effect of NL003 on angiogenesis and lower limb blood flow perfusion during the treatment of chronic lower limb ischemia, and evaluated the effectiveness and safety of the drug. The subjects will be randomly divided into the investigational drug group and the placebo group in a 1:1 ratio. NL003 or placebo will be injected into the muscle of the affected limb on D0, D14 and D28, 0.5mg/0.5mL/site, total 8mg, 32 sites. PET/CT will be measured on D14, D42 before drug administration, MIBI SPECT imaging will be collected on D60.

• Study Type: Interventional
• Enrollment (Estimated): 36
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Yue Liu, MM; Phone Number: 86-10-82890893; Email: liuyue@northland-bio.com
• Study Contact Backup: Name: Yinjian Sun, MS; Phone Number: +86-10-82890893; Email: sunyinjian@northland-bio.com

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100032
      • Recruiting
      • Peking Union Medical College Hospital
      • Principal Investigator: Changwei Liu
      • Sub-Investigator: Xiao Di

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. 18-80 years, diagnosed with chronic lower limb ischemia;
2. According to DSA or CTA，severe stenosis (≥70%) or occlusion of one or more branches of superficial femoral artery, popliteal artery, anterior tibial artery, posterior tibial artery, and peroneal artery.
3. Patients with obvious symptoms of lower limb ischemia, including severe claudication, resting pain, ulcers, or gangrene.
4. Agree to use appropriate contraceptive methods during the trial; Female subjects of reproductive age, blood pregnancy test negative.
5. Signing the informed consent.
6. Can complete PETCT-RGD check and MIBI check;

Exclusion Criteria:

1. The foot or lower limb infection cannot be controlled, and amputation may be accepted within 3 months.
2. Those with cerebral infarction, cerebral hemorrhage, heart failure, unstable angina, acute myocardial infarction, and serious arrhythmia within 3 months;
3. Tumor patients diagnosed with malignant tumor or suspected of having malignant tumor after tumor screening;
4. Main iliac artery stenosis ≥ 70%;
5. Refractory hypertension (taking three or more antihypertensive drugs, systolic blood pressure ≥ 180mmHg or diastolic blood pressure ≥ 110mmHg);
6. Anti HIV antibody positive person, anti hepatitis C antibody positive person and RNA positive person, hepatitis B surface antigen positive person (if the subject is HBsAg positive, and judging by peripheral blood HBV DNA, the researcher believes that the subject is in a stable period of chronic hepatitis B, which will not increase the risk of the subject, the subject can be selected)
7. Patients with poor blood glucose control after treatment (HbA1c>10%);
8. Persons allergic to contrast medium
9. The investigator believes that the patient's complications affect the evaluation of safety and effectiveness, or the expected survival period is less than 12 months;
10. Those who regularly drink more than 14 units of alcohol (1 unit=360 mL beer or 45 mL liquor or 150 mL wine with 40% alcohol) or drug abusers within 12 months before signing the informed consent form;
11. Acute lower limb ischemia or acute aggravation of chronic lower limb ischemia;
12. Those who received vascular reconstruction of the affected limb within 4 weeks before the informed consent form and whose blood supply improved after the operation
13. Serious liver or kidney disease or severe anemia judged by the investigator;
14. Those who cannot correctly describe symptoms and emotions;
15. Those who participated in other clinical trials within 3 months before signing the informed consent form.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: investigational product; Patients in this treatment group will receive 8mg NL003 respective in D0、14、28	Drug: NL003; Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003); Other Names: HGF plasmid; pCK-HGF-X7
Placebo Comparator: Placebo; Patients in this group will receive normal saline respective in D0、14、28	Drug: Placebo; Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections ) Other Name: Placebo; Other Names: Normal Saline

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes of the new blood vessels number	changes in the number of new blood vessels measured by PETCT-RGD on D14 and D42, compare with that of the baseline.	Day 14、Day 42
Changes of local blood perfusion	the changes of local blood perfusion measured by MIBI on D60, compare with that of baseline.	Day 60

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes to the ABI from the baseline	Ankle-brachial index (ABI) refers to the ratio of systolic blood pressure of the anterior tibial artery (dorsal foot artery) or posterior tibial artery to the systolic blood pressure of the brachial artery.Participants were tested for ankle-brachial index (ABI).	Day 60
Laser Speckle Imaging changes in blood flow from the baseline	Laser Speckle Imaging changes in blood flow from the baseline was measured on D60.	Day 60
Changes of pain score from the baseline	The severity of critical Limb ischemia was assessed by Rutherford grading at screening、D14、D28、D42、D60、D90	Day 14、Day 28、Day 42、Day 60、Day 90
Gangrene /Ulcer changes from the baseline	Changes in the area of ulcer or gangrene from baseline after use of the study drug	Day 14、Day 28、Day 42、Day 60、Day 90
Changes in quality of life scores from baseline	The quality of life score questionnaire was conducted to evaluate the subjective perception of Critical Limb Ischemia, including the subjects' perception of quality of life, health, or other aspects of life.	Day 60

Collaborators and Investigators

• Sponsor: Beijing Northland Biotech. Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): July 29, 2022
• Primary Completion (Estimated): July 31, 2023
• Study Completion (Estimated): October 31, 2023

Study Registration Dates

• First Submitted: January 4, 2023
• First Submitted That Met QC Criteria: July 20, 2023
• First Posted (Actual): August 1, 2023

Study Record Updates

• Last Update Posted (Actual): August 1, 2023
• Last Update Submitted That Met QC Criteria: July 20, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Keywords: Peripheral Artery Disease; Gene therapy; Hepatocyte Growth Factor; MIBI; NL003; PET/CT-RGD
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Atherosclerosis; Peripheral Vascular Diseases; Peripheral Arterial Disease
• Other Study ID Numbers: NL003-PAD-III-3

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No